Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2014

Open Access 01-12-2014 | Research article

Dephosphorylated-uncarboxylated Matrix Gla protein concentration is predictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients

Authors: Pierre Delanaye, Jean-Marie Krzesinski, Xavier Warling, Martial Moonen, Nicole Smelten, Laurent Médart, Hans Pottel, Etienne Cavalier

Published in: BMC Nephrology | Issue 1/2014

Login to get access

Abstract

Background

Matrix Gla protein (MGP) is known to act as a potent local inhibitor of vascular calcifications. However, in order to be active, MGP must be phosphorylated and carboxylated, with this last process being dependent on vitamin K. The present study focused on the inactive form of MGP (dephosphorylated and uncarboxylated: dp-ucMGP) in a population of hemodialyzed (HD) patients. Results found in subjects being treated or not with vitamin K antagonist (VKA) were compared and the relationship between dp-ucMGP levels and the vascular calcification score were assessed.

Methods

One hundred sixty prevalent HD patients were enrolled into this observational cohort study, including 23 who were receiving VKA treatment. The calcification score was determined (using the Kauppila method) and dp-ucMGP levels were measured using the automated iSYS method.

Results

dp-ucMGP levels were much higher in patients being treated with VKA and little overlap was found with those not being treated (5604 [3758; 7836] vs. 1939 [1419; 2841] pmol/L, p <0.0001). In multivariate analysis, treatment with VKA was the most important variable explaining variation in dp-ucMGP levels even when adjusting for all other significant variables. In the 137 untreated patients, dp-ucMGP levels were significantly (p < 0.05) associated both in the uni- and multivariate analysis with age, body mass index, plasma levels of albumin, C-reactive protein, and FGF-23, and the vascular calcification score.

Conclusion

We confirmed that the concentration of dp-ucMGP was higher in HD patients being treated with VKA. We observed a significant correlation between dp-ucMGP concentration and the calcification score. Our data support the theoretical role of MGP in the development of vascular calcifications. We confirmed the potential role of the inactive form of MGP in assessing the vitamin K status of the HD patients.

Trial registration

B707201215885
Appendix
Available only for authorised users
Literature
1.
Price PA, Urist MR, Otawara Y: Matrix Gla protein, a new gamma-carboxyglutamic acid-containing protein which is associated with the organic matrix of bone. Biochem Biophys Res Commun. 1983, 117: 765-771. 10.1016/0006-291X(83)91663-7.CrossRefPubMed
2.
Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G: Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997, 386: 78-81. 10.1038/386078a0.CrossRefPubMed
3.
Lomashvili KA, Wang X, Wallin R, O’Neill WC: Matrix Gla protein metabolism in vascular smooth muscle and role in uremic vascular calcification. J Biol Chem. 2011, 286: 28715-28722. 10.1074/jbc.M111.251462.CrossRefPubMedPubMedCentral
4.
Zebboudj AF, Imura M, Bostrom K: Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem. 2002, 277: 4388-4394. 10.1074/jbc.M109683200.CrossRefPubMed
5.
Murshed M, Schinke T, McKee MD, Karsenty G: Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol. 2004, 165: 625-630. 10.1083/jcb.200402046.CrossRefPubMedPubMedCentral
6.
Schurgers LJ, Spronk HM, Skepper JN, Hackeng TM, Shanahan CM, Vermeer C, Weissberg PL, Proudfoot D: Post-translational modifications regulate matrix Gla protein function: importance for inhibition of vascular smooth muscle cell calcification. J Thromb Haemost. 2007, 5: 2503-2511. 10.1111/j.1538-7836.2007.02758.x.CrossRefPubMed
7.
Schlieper G, Westenfeld R, Kruger T, Cranenburg EC, Magdeleyns EJ, Brandenburg VM, Djuric Z, Damjanovic T, Ketteler M, Vermeer C, Dimkovic N, Floege J, Schurgers LJ: Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. J Am Soc Nephrol. 2011, 22: 387-395. 10.1681/ASN.2010040339.CrossRefPubMedPubMedCentral
8.
Cranenburg EC, Koos R, Schurgers LJ, Magdeleyns EJ, Schoonbrood TH, Landewe RB, Brandenburg VM, Bekers O, Vermeer C: Characterisation and potential diagnostic value of circulating matrix Gla protein (MGP) species. Thromb Haemost. 2010, 104: 811-822. 10.1160/TH09-11-0786.CrossRefPubMed
9.
Schurgers LJ, Cranenburg EC, Vermeer C: Matrix Gla-protein: the calcification inhibitor in need of vitamin K. Thromb Haemost. 2008, 100: 593-603.PubMed
10.
Westenfeld R, Krueger T, Schlieper G, Cranenburg EC, Magdeleyns EJ, Heidenreich S, Holzmann S, Vermeer C, Jahnen-Dechent W, Ketteler M, Floege J, Schurgers LJ: Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. Am J Kidney Dis. 2012, 59: 186-195. 10.1053/j.ajkd.2011.10.041.CrossRefPubMed
11.
Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC: Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis. 1996, 27: 394-401. 10.1016/S0272-6386(96)90363-7.CrossRefPubMed
12.
Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000, 342: 1478-1483. 10.1056/NEJM200005183422003.CrossRefPubMed
13.
Jean G, Bresson E, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C: Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant. 2009, 24: 948-955.CrossRefPubMed
14.
Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F: Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation. 2002, 106: 100-105. 10.1161/01.CIR.0000020222.63035.C0.CrossRefPubMed
15.
Adragao T, Pires A, Birne R, Curto JD, Lucas C, Goncalves M, Negrao AP: A plain X-ray vascular calcification score is associated with arterial stiffness and mortality in dialysis patients. Nephrol Dial Transplant. 2009, 24: 997-1002.CrossRefPubMed
16.
London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003, 18: 1731-1740. 10.1093/ndt/gfg414.CrossRefPubMed
17.
Schlieper G, Kruger T, Djuric Z, Damjanovic T, Markovic N, Schurgers LJ, Brandenburg VM, Westenfeld R, Dimkovic S, Ketteler M, Grootendorst DC, Dekker FW, Floege J, Dimkovic N: Vascular access calcification predicts mortality in hemodialysis patients. Kidney Int. 2008, 74: 1582-1587. 10.1038/ki.2008.458.CrossRefPubMed
18.
Schurgers LJ: Vitamin K: key vitamin in controlling vascular calcification in chronic kidney disease. Kidney Int. 2013, 83: 782-784. 10.1038/ki.2013.26.CrossRefPubMed
19.
Holden RM, Morton AR, Garland JS, Pavlov A, Day AG, Booth SL: Vitamins K and D status in stages 3–5 chronic kidney disease. Clin J Am Soc Nephrol. 2010, 5: 590-597. 10.2215/CJN.06420909.CrossRefPubMedPubMedCentral
20.
Pilkey RM, Morton AR, Boffa MB, Noordhof C, Day AG, Su Y, Miller LM, Koschinsky ML, Booth SL: Subclinical vitamin K deficiency in hemodialysis patients. Am J Kidney Dis. 2007, 49: 432-439. 10.1053/j.ajkd.2006.11.041.CrossRefPubMed
21.
Cranenburg EC, Schurgers LJ, Uiterwijk HH, Beulens JW, Dalmeijer GW, Westerhuis R, Magdeleyns EJ, Herfs M, Vermeer C, Laverman GD: Vitamin K intake and status are low in hemodialysis patients. Kidney Int. 2012, 82: 605-610. 10.1038/ki.2012.191.CrossRefPubMed
22.
Fusaro M, Noale M, Viola V, Galli F, Tripepi G, Vajente N, Plebani M, Zaninotto M, Guglielmi G, Miotto D, Dalle CL, D'Angelo A, Naso A, Grimaldi C, Miozzo D, Giannini S, Gallieni M: Vitamin K, vertebral fractures, vascular calcifications, and mortality: VItamin K Italian (VIKI) dialysis study. J Bone Miner Res. 2012, 27: 2271-2278. 10.1002/jbmr.1677.CrossRefPubMed
23.
Boxma PY, van den Berg E, Geleijnse JM, Laverman GD, Schurgers LJ, Vermeer C, Kema IP, Muskiet FA, Navis G, Bakker SJ, de Borst MH: Vitamin k intake and plasma desphospho-uncarboxylated matrix Gla-protein levels in kidney transplant recipients. PLoS One. 2012, 7: e47991-10.1371/journal.pone.0047991.CrossRefPubMedPubMedCentral
24.
Voong K, Harrington D, Goldsmith D: Vitamin K status in chronic kidney disease: a report of a study and a mini-review. Int Urol Nephrol. 2013, 45: 1339-1344. 10.1007/s11255-012-0367-x.CrossRefPubMed
25.
Schurgers LJ, Barreto DV, Barreto FC, Liabeuf S, Renard C, Magdeleyns EJ, Vermeer C, Choukroun G, Massy ZA: The circulating inactive form of matrix gla protein is a surrogate marker for vascular calcification in chronic kidney disease: a preliminary report. Clin J Am Soc Nephrol. 2010, 5: 568-575. 10.2215/CJN.07081009.CrossRefPubMedPubMedCentral
26.
Shea MK, O’Donnell CJ, Vermeer C, Magdeleyns EJ, Crosier MD, Gundberg CM, Ordovas JM, Kritchevsky SB, Booth SL: Circulating uncarboxylated matrix gla protein is associated with vitamin K nutritional status, but not coronary artery calcium, in older adults. J Nutr. 2011, 141: 1529-1534. 10.3945/jn.111.139634.CrossRefPubMedPubMedCentral
27.
Caluwe R, Vandecasteele S, Van VB, Vermeer C, De Vriese AS: Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study. Nephrol Dial Transplant. 2014, 29: 1385-1390. 10.1093/ndt/gft464.CrossRefPubMed
28.
Shea MK, O’Donnell CJ, Hoffmann U, Dallal GE, Dawson-Hughes B, Ordovas JM, Price PA, Williamson MK, Booth SL: Vitamin K supplementation and progression of coronary artery calcium in older men and women. Am J Clin Nutr. 2009, 89: 1799-1807. 10.3945/ajcn.2008.27338.CrossRefPubMedPubMedCentral
29.
Dalmeijer GW, van der Schouw YT, Vermeer C, Magdeleyns EJ, Schurgers LJ, Beulens JW: Circulating matrix Gla protein is associated with coronary artery calcification and vitamin K status in healthy women. J Nutr Biochem. 2013, 24: 624-628. 10.1016/j.jnutbio.2012.02.012.CrossRefPubMed
30.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009, 113: S1-130.
31.
Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW: New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis. 1997, 132: 245-250. 10.1016/S0021-9150(97)00106-8.CrossRefPubMed
32.
Ueland T, Gullestad L, Dahl CP, Aukrust P, Aakhus S, Solberg OG, Vermeer C, Schurgers LJ: Undercarboxylated matrix Gla protein is associated with indices of heart failure and mortality in symptomatic aortic stenosis. J Intern Med. 2010, 268: 483-492. 10.1111/j.1365-2796.2010.02264.x.CrossRefPubMed
33.
Rennenberg RJ, Schurgers LJ, Vermeer C, Scholte JB, Houben AJ, de Leeuw PW, Kroon AA: Renal handling of matrix Gla-protein in humans with moderate to severe hypertension. Hypertens Res. 2008, 31: 1745-1751. 10.1291/hypres.31.1745.CrossRefPubMed
34.
Krueger T, Schlieper G, Schurgers L, Cornelis T, Cozzolino M, Jacobi J, Jadoul M, Ketteler M, Rump LC, Stenvinkel P, Westenfeld R, Wiecek A, Reinartz S, Hilgers RD, Floege J: Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): a rationale and study protocol. Nephrol Dial Transplant. 2014, 29: 1633-1638. 10.1093/ndt/gft459.CrossRefPubMed
35.
Cianciolo G, La Manna G, Donati G, Persici E, Dormi A, Cappuccilli ML, Corsini S, Fattori R, Russo V, Nastasi V, Coli L, Wratten M, Stefoni S: Coronary calcifications in end-stage renal disease patients: a new link between osteoprotegerin, diabetes and body mass index?. Blood Purif. 2010, 29: 13-22. 10.1159/000245042.CrossRefPubMed
36.
Cranenburg EC, Brandenburg VM, Vermeer C, Stenger M, Muhlenbruch G, Mahnken AH, Gladziwa U, Ketteler M, Schurgers LJ: Uncarboxylated matrix Gla protein (ucMGP) is associated with coronary artery calcification in haemodialysis patients. Thromb Haemost. 2009, 101: 359-366.PubMed
37.
Hermans MM, Vermeer C, Kooman JP, Brandenburg V, Ketteler M, Gladziwa U, Rensma PL, Leunissen KM, Schurgers LJ: Undercarboxylated matrix GLA protein levels are decreased in dialysis patients and related to parameters of calcium-phosphate metabolism and aortic augmentation index. Blood Purif. 2007, 25: 395-401. 10.1159/000108629.CrossRefPubMed
38.
Jono S, Ikari Y, Vermeer C, Dissel P, Hasegawa K, Shioi A, Taniwaki H, Kizu A, Nishizawa Y, Saito S: Matrix Gla protein is associated with coronary artery calcification as assessed by electron-beam computed tomography. Thromb Haemost. 2004, 91: 790-794.PubMed
39.
McCabe KM, Booth SL, Fu X, Shobeiri N, Pang JJ, Adams MA, Holden RM: Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease. Kidney Int. 2013, 83: 835-844. 10.1038/ki.2012.477.CrossRefPubMed
40.
Brandenburg VM, Kramann R, Specht P, Ketteler M: Calciphylaxis in CKD and beyond. Nephrol Dial Transplant. 2012, 27: 1314-1318. 10.1093/ndt/gfs015.CrossRefPubMed
41.
Chan KE, Lazarus JM, Thadhani R, Hakim RM: Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009, 20: 2223-2233. 10.1681/ASN.2009030319.CrossRefPubMedPubMedCentral
42.
Koos R, Mahnken AH, Muhlenbruch G, Brandenburg V, Pflueger B, Wildberger JE, Kuhl HP: Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Am J Cardiol. 2005, 96: 747-749. 10.1016/j.amjcard.2005.05.014.CrossRefPubMed
43.
Price PA, Faus SA, Williamson MK: Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol. 1998, 18: 1400-1407. 10.1161/01.ATV.18.9.1400.CrossRefPubMed
44.
Palaniswamy C, Sekhri A, Aronow WS, Kalra A, Peterson SJ: Association of warfarin use with valvular and vascular calcification: a review. Clin Cardiol. 2011, 34: 74-81. 10.1002/clc.20865.CrossRefPubMed
45.
Schurgers LJ, Joosen IA, Laufer EM, Chatrou ML, Herfs M, Winkens MH, Westenfeld R, Veulemans V, Krueger T, Shanahan CM, Jahnen-Dechent W, Biessen E, Narula J, Vermeer C, Hofstra L, Reutelingsperger CP: Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype. PLoS One. 2012, 7: e43229-10.1371/journal.pone.0043229.CrossRefPubMedPubMedCentral
46.
Holden RM, Sanfilippo AS, Hopman WM, Zimmerman D, Garland JS, Morton AR: Warfarin and aortic valve calcification in hemodialysis patients. J Nephrol. 2007, 20: 417-422.PubMed
47.
Krueger T, Westenfeld R, Ketteler M, Schurgers LJ, Floege J: Vitamin K deficiency in CKD patients: a modifiable risk factor for vascular calcification?. Kidney Int. 2009, 76: 18-22. 10.1038/ki.2009.126.CrossRefPubMed
48.
Spronk HM, Soute BA, Schurgers LJ, Thijssen HH, De Mey JG, Vermeer C: Tissue-specific utilization of menaquinone-4 results in the prevention of arterial calcification in warfarin-treated rats. J Vasc Res. 2003, 40: 531-537. 10.1159/000075344.CrossRefPubMed
Metadata
Title
Dephosphorylated-uncarboxylated Matrix Gla protein concentration is predictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients
Authors
Pierre Delanaye
Jean-Marie Krzesinski
Xavier Warling
Martial Moonen
Nicole Smelten
Laurent Médart
Hans Pottel
Etienne Cavalier
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2014
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-15-145

Other articles of this Issue 1/2014

BMC Nephrology 1/2014 Go to the issue

Research article

A self-report comorbidity questionnaire for haemodialysis patients

Case report

Tubulointerstitial nephritis complicating IVIG therapy for X-linked agammaglobulinemia

Research article

A randomized trial of sodium-restriction on kidney function, fluid volume and adipokines in CKD patients

Research article

Detection of renal allograft rejection using blood oxygen level-dependent and diffusion weighted magnetic resonance imaging: a retrospective study

Research article

Determination of vancomycin and gentamicin clearance in an in vitro, closed loop dialysis system

Study protocol

A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits